BACOD方案治疗复发及难治性非霍奇金淋巴瘤的临床研究

 目的　观察BACOD方案治疗复发及难治性非霍奇金淋巴瘤（NHL）的疗效及患者不良反应。方法　65例复发及难治性NHL患者，采用BACOD方案进行化疗，具体为：博莱霉素10 mg／m2，静脉滴注，第2、9天；环磷酰胺750 mg／m2，静脉滴注，第1天；长春地辛3 mg／m2，静脉注射，第1、8天；阿糖胞苷150 mg／m2，静脉滴注，第2天至第5天；地塞米松10 mg／m2，静脉滴注，第1天至第7天，3周为1个疗程。结果　完全缓解18例，部分缓解30例，稳定13例，进展4例，有效率70.8 %。有效患者中位缓解时间 10个月（2～35个月）。1年生存率32.3 %，2年生存率24.6 %。患者主要不良反应为骨髓抑制。结论　BACOD方案可作为复发及难治性NHL的解救方案。

Clinical study of BACOD regimen of relapsed and refractory non-Hodgkin lymphoma

Objective To investigate the efficacy and adverse events of BACOD regimen for relapsed and refractory non-Hodgkin lymphoma (NHL). Methods Sixty patients with relapsed and refractory NHL received chemotherapy of BACOD regimen: bleomycin 10 mg/m2, intravenous drip on the 2nd and 9th day;cyclophosphamide 750 mg/m2, intravenous drip on 1st day; vindesine 3 mg/m2, intravenous drip on 1st and 8th day; cytarabine 150 mg/m2, intravenous drip on 2nd-5th days; dexamethasone 10 mg/m2, intravenous drip on 2nd-5th days; every 3 weeks was one cycle. Results Eighteen cases (27.7 %) received the complete remission (CR), 30 the partial remission (PR), 13 stable disease (SD) and 4 progressive disease (PD). The overall response (CR+PR) rate was 70.8 %. The median remission time of patients with response was 11 months(2-38 months). The 1-year survival rate was 32.3 % and the 2-year survival rate was 24.6 %. The main adverse events were myelosuppression. Conclusion BACOD regimen can be used as the relief regimen of relapsed and refractory NHL.